DEPOMED WKN: A2N4B9 ISIN: US04545L1070 Kürzel: ASRT Forum: Aktien Thema: Hauptdiskussion

Assertio Therapeutics EPS beats by $0.18, beats on revenue https://seekingalpha.com/news/3572647-assertio-therapeutics-eps-beats-0_18-beats-on-revenue

Assertio Therapeutics: A Biotech Stock Trading Below Its Cash Balance https://seekingalpha.com/article/4324469-assertio-therapeutics-biotech-stock-trading-below-cash-balance Takeaway ASRT has seen its fair share of woes, from the recent rejection of its cosyntropin sNDA, to below-average data readout on collaboration project IW-3718, and to a staggering -20% Y/Y decline on core product revenues. On the other hand, the recent sale of Nucynta for $375M removes all remaining debt from the company's balance sheet, causes its stock to trade at negative enterprise value, and adds sizable capital for future R&D efforts. Keep in mind, ASRT is estimated to continue its profitability after the deal closes, as its remaining products have over 60-80% gross margin. Hence, the author finds the benefit to outweigh the company's drawbacks, and will reiterate the company's buy rating as of today.

Letztes Jahr mit Verlust raus 🤤

Assertio Therapeutics Announces Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 Million https://newsfilter.io/a/3d0fa5d5f5e45ad603002142755aedb8

😎

👀

Assertio Therapeutics Sees FY19 Neurology Franchise Sales Above Guidance Range Of $102M-$105M

Assertio Therapeutics Announces Closing Of Gralise Sale To Alvogen; Co. To Receive $127.5M

Assertio pipeline products https://www.assertiotx.com/products-and-pipeline/pipeline/ Zwei Medikamente stehen vor dem Approvel

Assertio (ASRT) Upgraded to Strong Buy: What Does It Mean for the Stock? https://finance.yahoo.com/news/assertio-asrt-upgraded-strong-buy-170005299.html The upgrade of Assertio to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

ASRT vs. PCRX: Which Stock Is the Better Value Option? https://finance.yahoo.com/news/asrt-vs-pcrx-stock-better-164004569.html ASRT sticks out from PCRX in both our Zacks Rank and Style Scores models, so value investors will likely feel that ASRT is the better option right now

Karmate, was erwartet du hier ?

Es geht los